• Matridx

  Participated · Series A · Mar 2020

  Jieyi Biotech focuses on R&D, manufacturing, and sales of products for large-scale analysis of genetic variation, gene function, and pathogen microorganism detection, and provides integrated AI system solutions. Its product scope covers tools for genetic-variation analysis, gene-function studies, and pathogen detection. The company recently completed a C+ round financing totaling several hundred million RMB. Investors in the round included Kuntai Fund, Yuhang State Investment Group and other industrial investors. The financing will be used to advance the product pipeline R&D, register medical device products, and implement commercial-application strategies. Jieyi Biotech aims to accelerate its leadership in the pathogen-precision-medicine segment. 杰毅生物 develops high-throughput sequencing (NGS) and CRISPR/Cas-based molecular diagnostic solutions focused on infectious disease detection, including a proprietary automated pathogen metagenomics (mNGS) testing product and a Q-mNGS quantitative offering. The company positions its mNGS solution as faster, more accurate, and with broader service coverage in China, and reports nearly 20 patent and IP applications. It has partnered with top clinical centers (e.g., Peking Union Medical College Hospital, Huashan Hospital, Guangzhou Respiratory Health Research Institute) and with industry partners including Alibaba Cloud on AI applications and Illumina on microbiome applications. During COVID-19, the company led national emergency testing projects, built an mNGS sequencing center in Wuhan, supported CDCs and produced a CRISPR-based rapid SARS-CoV-2 test and POCT device that obtained CE certification. The company plans to continue product development, regulatory registration of infection-line medical devices, and commercialization expansion. Hangzhou Jieyi Biotechnology focuses on infectious disease diagnostics using high-throughput sequencing (NGS) and CRISPR/Cas platforms. The company offers a fully automated pathogen metagenomics (mNGS) detection product solution and has developed the NGSmaster automated library-preparation device to simplify workflows and accelerate testing (reported to be about eight hours faster than existing solutions). Jieyi is a strategic partner with Alibaba Cloud on infectious disease AI applications and has collaborated with Alibaba’s Damo Academy to cloud-enable and automate bioinformatics analysis. During the COVID-19 pandemic, its mNGS automated solution was deployed across CDCs in Hubei, Zhejiang, and Jiangsu and a localized sequencing center was built at Wuhan Jinyintan Hospital, supporting precise diagnosis for over 300 severe COVID-19 patients. The company has signed a commercial cooperation agreement with Illumina for NGS applications in pathogen diagnostics and maintains research collaborations with leading clinical institutions such as Peking Union Medical College Hospital, Huashan Hospital (Fudan), and Shao Yifu Hospital (Zhejiang University). Jieyi is actively advancing NMPA registration for its product. 杰毅生物 (Jieyi Biotech) develops automated pathogen metagenomics (mNGS) and CRISPR/Cas-based diagnostic products and services. Its core product line includes NGSmaster, a fully automated library-preparation device, and an mNGS product solution that the company says is faster (about 8 hours quicker than similar products), operable inside biosafety cabinets with one-click operation, and covers over 16,800 pathogen species. The company combines high-throughput sequencing (NGS) and gene-editing (CRISPR) platforms with data-driven product innovation, and is a strategic partner of Alibaba Cloud on infectious-disease AI applications. Its solutions are already deployed in Hubei, Zhejiang, Jiangsu CDCs and major medical institutions and have been localized at Wuhan Jinyintan Hospital to support COVID-19 response. The founding team includes members from Berry Genomics and a former partner of the Zhejiang Big Health Industry Fund. The company completed its first institutional financing and plans to use proceeds to register mNGS equipment and reagent kits and to build a testing service network.

No current team members are available.